![Frontiers | A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity | Oncology Frontiers | A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity | Oncology](https://www.frontiersin.org/files/Articles/598477/fonc-10-598477-HTML/image_m/fonc-10-598477-g001.jpg)
Frontiers | A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity | Oncology
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation - Simply Wall St News
![Champions Oncology: Emerging Pick And Shovel Play On Cancer Drug Development (NASDAQ:CSBR) | Seeking Alpha Champions Oncology: Emerging Pick And Shovel Play On Cancer Drug Development (NASDAQ:CSBR) | Seeking Alpha](https://static.seekingalpha.com/uploads/2019/3/20/1037712-1553102662763556_origin.jpeg)